13.82 USD
▼+0.63-3.56%
盘后 14.48 +1.05%
2026-08-03
市值
$791.64M
市盈率
—
EPS
-1.47
股息率
—
52 周区间
5.78 – 19.40
成交量
2.25M
Beta
0.92
目标价
35.30
52W 低 5.7852W 高 19.40
价格走势
公司简介
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and ch...